Immunological markers of anti-tumor dendritic cells vaccine efficiency in patients with non-small cell lung cancer

Experimental Oncology

Volumn 35, Issue 2, 2013, Pages 109-113

  Skachkova, O V ^a   Khranovska, N M ^a   Gorbach, O I ^a   Svergun, N M ^a   Sydor, R I ^a   Nikulina, V V ^a  

^a NATIONAL CANCER INSTITUTE   (Ukraine)

Author keywords

Chemokines; DC vaccine; Effector cells; Immunological monitoring; Lung cancer

Indexed keywords

DENDRITIC CELL VACCINE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MESSENGER RNA; RANTES;

ADULT; AGED; ARTICLE; CANCER PATIENT; CD4 CD8 RATIO; CELL COUNT; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNE SYSTEM; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; NATURAL KILLER CELL; PERIPHERAL LYMPHOCYTE; PHASE 3 CLINICAL TRIAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CANCER VACCINES; CARCINOMA, NON-SMALL-CELL LUNG; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CHEMOKINE CCL3; CHEMOKINE CCL5; CYTOKINES; DENDRITIC CELLS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOTHERAPY; INTERFERON-GAMMA; KILLER CELLS, NATURAL; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84880855003     PISSN: 18129269     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Zahir S, Mirtalebi M. Survival of patients with lung cancer, Yazd, Iran. Asian Pac J Cancer Prev 2012; 13: 4387-91.
2. Fedorenko ZP, Gajsenko AV, Goulak LO, et al. Cancer in Ukraine 2010-2011. Bulletin of National Cancer Registry of Ukraine. Ed. By IB Shchepotin. Kyiv, 2012; 13: 33-4.
3. Ozkaya S, Findik S, Dirican A, Atici A. Long-term survival rates of patients with stage IIIB and IV non-small cell lung cancer treated with cisplatin plus vinorelbine or gemcitabine. Exp Ther Med 2012; 4: 1035-8.
4. Kratz J, He J, Van Den Eeden S, Zhu Z, Gao W. A practical molecular assay to predict survival in resected non-squamous, non-small-cell lung cancer: development and international validation studies. Lancet 2012; 379: 823-32.
5. Ploenes T, Scholtes B, Krohn A, et al. CC-chemokine ligand 18 induces epithelial to mesenchymal transition in lung cancer A549 cells and elevates the invasive potential. PLoS One 2013; 8: 61-8.
6. Ganul AV, Khranovskaya NN, Sovenko VM, et al. Experience of using dendritic cell autovaccine in non-small-cell lung cancer patients. Clin Oncology 2012; 3: 21-5.
7. Tuyaerts S. Dendritic cell therapy for oncology roundtable conference. J Immune Based Ther Vaccines 2011; 9: 1-7.
8. Fox BA, Schendel DJ, et al. Defining the critical hurdles in cancer immunotherapy. J Transl Med 2011; 9: 214-27.
9. Hoos A. Evolution of end points for cancer immunotherapy trials. Ann Oncol 2012; 8: 47-52.
10. González-Martín A, Gómez L, Lustgarten J, et al. Maximal T cell-mediated antitumor responses rely upon CCR5 expression in both CD4(+) and CD8(+) T cells. Cancer Res 2011; 71: 5455-66.
11. González-Martín A, Mira E, Mañes S. CCR5 in cancer immunotherapy: More than an "attractive" receptor for T cells. Oncoimmunology 2012; 1: 106-8.
12. Singh R, Singh S, Briles DE, et al. CCL5-independent helper T lymphocyte responses to immuno-dominant pneumococcal surface protein A epitopes. Vaccine 2012; 30: 1181-90.
13. De Buck M, Gouwy M, Proost P, et al. Identification and characterization of MIP-1α/CCL3 isoform 2 from bovine serum as a potent monocyte/dendritic cell chemoattractant. Biochem Pharmacol 2013; 85: 789-97.
14. Lillard JW, Singh UP, Boyaka PN, et al. MIP-1alpha and MIP-1beta differentially mediate mucosal and systemic adaptive immunity. Blood 2003; 101: 807-14.